A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Clinical trial NCT05564052 · COMPLETED
Trial details
- NCT number
- NCT05564052
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-06
- Primary completion
- 2023-12-06
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.